HEMA Biologics

About

HEMA Biologics is a specialized pharmaceutical company based in Louisville, Kentucky, dedicated to developing innovative treatments for patients with rare bleeding disorders. The company has established itself as a leader in hemophilia care through the development of SEVENFACT, the first inhibitor bypassing agent approved in over 20 years for treating hemophilia A or B patients with inhibitors. HEMA Biologics operates comprehensive clinical research programs, including the PERSEPT clinical trial series, to advance treatment efficacy and patient outcomes. The company maintains a strong commitment to investigator-initiated research and collaborates extensively with the medical community to support clinical trials and patient care initiatives. Their dedicated medical affairs team provides specialized support to healthcare professionals treating patients with bleeding disorders. Located at their Louisville facility, HEMA Biologics combines pharmaceutical manufacturing capabilities with research excellence to deliver meaningful treatments that improve daily lives for patients with these challenging conditions. The company actively engages with patient advocacy groups and healthcare providers to ensure their innovations address real-world treatment needs and gaps in care for this underserved patient population.